Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
SAN DIEGO and CALGARY, AB, June 11, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a member of its Board of Directors.
Mr. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy. Most recently, he played a central role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for $2 billion. Prior to Ambrx, he advised multiple leading-edge biotech companies on M&A and licensing transactions at highly respected law firms, including Lowenstein Sandler LLP and Kirkland & Ellis LLP. He is a JD and LLM graduate of Georgetown Law.
"Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of Oncolytics' Board of Directors and outgoing Interim CEO. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors."
Mr. Kelly added, "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients. With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders."
Pelareorep, an intravenously-administered immunotherapeutic agent, has been granted FDA Fast Track designation by the U.S. Food and Drug Administration (FDA) in metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC). It has delivered compelling results in mPDAC, a high-value indication with significant unmet need. In Phase 1 and 2 trials involving more than 140 mPDAC patients, pelareorep has delivered a >60% objective response rate in tumor evaluable patients in the most recent study, which is more than double the benefit observed in historical control trials, and, separately, two-year survival rates 4-6 times those observed in control patients or against the benchmark in prior studies.
In mBC, pelareorep recorded a meaningful survival benefit in two randomized Phase 2 studies of over 100 combined mBC patients, IND-213 and BRACELET-1. Phase 2 objective response rate data in second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA) patients continue to exceed historical data for treatment with a checkpoint inhibitor alone. These consistent efficacy signals, in combination with multiple chemotherapies and checkpoint inhibitors, uniquely position pelareorep as a high-potential asset for further development in-house and/or through strategic partnerships. Pelareorep also has a well-defined and favorable safety profile based on data from >1,100 patients across multiple tumor types.
As a material inducement to Mr. Kelly's appointment as Chief Executive Officer, and in accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Kelly has been awarded an initial stock option grant exercisable for 2,850,000 shares with an exercise price of CAD$0.57, vesting equally over three years. He also received a performance-based stock option grant exercisable for 1,900,000 shares with an exercise price of CAD$0.57, which will vest upon the achievement of certain financing objectives. All stock option grants have a term of 5 years from the date of grant. The Company also granted Mr. Kelly restricted stock units, which will entitle him to receive that number of Common Shares equal to 2% of the Company's then outstanding common shares upon the Company entering into a definitive agreement for certain transactions providing for the acquisition of the Company or the exclusive license of pelareorep. Each of these awards is intended to align Mr. Kelly's long-term incentives with the creation of shareholder value.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @ oncolytics.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; Oncolytics' belief that pelareorep's consistent efficacy signals, in combination with multiple chemotherapies and checkpoint inhibitors, uniquely position pelareorep as a high-potential asset for further development in-house and/or through strategic partnerships; our belief that we will move pelareorep forward effectively and efficiently to a place where prospective partners will see potential value; our plans and strategies to advance pelareorep towards registrational studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics. ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors. com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Are the Dow, S&P 500, and Nasdaq Composite Going to Plunge? This Historically Accurate Forecasting Tool Offers a Crystal-Clear Answer.
Investors have no shortage of ways to grow their wealth over time. They can buy real estate, put their money to work in fixed-income assets like certificates of deposit or U.S. Treasury bonds, and can purchase commodities like oil, gold, and silver. However, no other asset class has come within a stone's throw of stocks over the last century on an annualized return basis. But just because stocks are the premier asset class to own over multiple decades, it doesn't mean Wall Street's major indexes move up in a straight line. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The iconic Dow Jones Industrial Average (DJINDICES: ^DJI), broad-based S&P 500 (SNPINDEX: ^GSPC), and growth-propelled Nasdaq Composite (NASDAQINDEX: ^IXIC), have endured their fair share of corrections, bear markets, and even crashes since their respective inceptions. In just a one-week period in early April, we observed the fifth-largest two-day percentage drop for the S&P 500 dating back to 1950, as well as the largest single-day nominal point gain for the Dow Jones, S&P 500, and Nasdaq Composite since their respective inceptions. When the market gyrates, it's perfectly normal for investors to dig for clues as to which direction stocks will move next. Even though no metric or predictive tool can guarantee what's to come, it's hard to overlook the statistical correlations that some data points and events have offered over the years. One forecasting tool, which occurs infrequently but has a historically flawless track record of correlating with big moves on Wall Street, has a crystal-clear message for investors: Prepare for eventual downside. More than 150 years of history points to trouble ahead for the Dow, S&P 500, and Nasdaq To preface the following discussion, there's always a data point, correlative event, or X factor threatening to cause the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite to plunge. Despite this, these indexes have motored higher over longer periods. But based on one value-focused forecasting measure, the good times are, eventually, set to end for Wall Street's major stock indexes. When investors think of the word "value," the price-to-earnings (P/E) ratio probably comes to mind. This quick-and-easy valuation measure can be arrived at by taking a company's share price and dividing it by its trailing-12-month earnings per share (EPS). The traditional P/E ratio works great for mature businesses, but it's not always a reliable valuation tool for growth stocks or during recessions. The valuation tool that offers a flawless forecasting track record when back-tested more than 150 years is the S&P 500's Shiller P/E Ratio. You'll occasionally see the Shiller P/E referred to as the cyclically adjusted P/E Ratio, or CAPE Ratio. Unlike the traditional P/E ratio, the Shiller P/E is based on average inflation-adjusted EPS over the trailing decade. Encompassing 10 years' worth of earnings history ensures that recessions don't adversely skew the results. S&P 500 Shiller CAPE Ratio data by YCharts. As of the closing bell on June 18, the S&P 500's Shiller P/E Ratio stood at a multiple of 36.55. To put this into perspective, it's 112% above the average multiple of 17.25, when back-tested to January 1871. However, this massive deviation from the historical mean isn't the telltale sign of trouble for Wall Street. What's far more concerning is how stocks have behaved following the rare instances where the Shiller P/E surpassed and held a multiple of 30 for a period of at least two months. Surpassing and sustaining 30 has occurred only six times in 154 years: August to September 1929 June 1997 to August 2001 September 2017 to November 2018 December 2019 to February 2020 August 2020 to May 2022 November 2023 to present Excluding the present, all five prior instances were eventually followed by declines ranging from 20% to 89% in the Dow Jones Industrial Average, S&P 500, and/or Nasdaq Composite. To be clear, the Shiller P/E isn't a timing tool and can't, in any way, pinpoint when stock market corrections, bear markets, or crashes will begin. But what it does have an exceptional track record of doing is foreshadowing an eventual plunge in Wall Street's three major stock indexes. Based solely on what history tells us, stocks won't be able to hold onto their current valuation premium, and the Dow, S&P 500, and Nasdaq Composite will, at some point in the presumed not-too-distant future, plunge. History is a pendulum that swings (disproportionately) in both directions Considering that the S&P 500 has enjoyed one of its strongest two-month performances in 75 years, the prospect of the index once again plunging probably doesn't sit well with investors. There's simply no getting around the data that lofty valuation premiums aren't well tolerated on Wall Street over long periods. But there is a major silver lining to this forecast. Specifically, history is a pendulum that swings in both directions and has disproportionately favored investors who've taken a long-term, optimistic approach. As noted, the Dow Jones, S&P 500, and Nasdaq Composite tend to climb over long periods, but their directional movements over shorter timelines are anything but predictable. Corrections, bear markets, and even crashes are normal, healthy, and inevitable aspects of the investing cycle. No amount of well-wishing or fiscal/monetary policy maneuvering can prevent Wall Street's major stock indexes from occasionally declining by double-digit percentages. However, the one noteworthy characteristic about double-digit percentage declines on Wall Street is they tend to be short-lived. Two years ago, shortly after the benchmark S&P 500 established that it was in a new bull market, the analysts at Bespoke Investment Group published a data set on X (formerly Twitter) that compared the calendar-day length of every bull and bear market for the S&P 500 dating back to the start of the Great Depression in September 1929. It's official. A new bull market is confirmed. The S&P 500 is now up 20% from its 10/12/22 closing low. The prior bear market saw the index fall 25.4% over 282 days. Read more at -- Bespoke (@bespokeinvest) June 8, 2023 On one hand, the typical bear market swoon lasted just 286 calendar days, which isn't even an average of 10 months. Conversely, the average S&P 500 bull market endured for 1,011 calendar days, or approximately 3.5 times as long. Being patient and optimistic has allowed investors to take advantage of this simple numbers game. A separate analysis from Crestmont Research widened the lens even further. Its analysts calculated the rolling 20-year total returns, including dividends paid, of the S&P 500 dating back to the start of the 20th century. For those of you rightly recognizing that the S&P didn't exist prior to 1923, Crestmont tracked the performance of its components in other major indexes from 1900 to 1923 in order to back-test its total return data more than a century. What Crestmont Research discovered was that all 106 rolling 20-year periods it examined (1900-1919, 1901-1920, and so on, to 2005-2024) generated a positive annualized total return. Hypothetically, they would have all made investors money, as long as investors held their position for 20 years. Regardless of what any forecasting tool suggests will happen in the coming weeks, months, or couple of years, more than a century of total return data demonstrates the power of buying stocks and holding them over long periods. Should you invest $1,000 in S&P 500 Index right now? Before you buy stock in S&P 500 Index, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and S&P 500 Index wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
9 hours ago
- Globe and Mail
enCore Energy Announces Filing of Early Warning Report
DALLAS , June 20, 2025 /CNW/ - enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the "Company" or "enCore"), America's Clean Energy Company ™, announces that it has disposed of 170,000,000 common shares in the capital of Anfield Energy Inc. (" Anfield") (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT : 0AD) in a private agreement at a price of $0.115 per share for aggregate proceeds of $19,550 ,000 (Canadian dollars). Immediately following the disposition, enCore holds or controls no common shares of Anfield. The disposition represents a 14.73% decrease in enCore's ownership or control over the outstanding common shares of Anfield on an undiluted basis. enCore does not currently hold or control any securities of Anfield . Since enCore's last early warning report dated January 15, 2024 , enCore's holdings have decreased by an approximate 16.02% of the outstanding common shares of Anfield on an undiluted basis. enCore disposed of the shares of Anfield in a private transaction. enCore may, depending on market and other conditions, increase beneficial ownership of the Company's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities. The disclosure respecting enCore's shareholdings contained in this news release is made pursuant to National Instrument 62-103 and a report respecting the above disposition will be filed with the applicable securities commissions and will be available for viewing at A copy of the report may also be obtained by contacting Robert Willette , Acting Chief Executive Officer, or at info@ About enCore Energy Corp. enCore Energy Corp., America's Clean Energy Company ™, is committed to providing clean, reliable, and affordable fuel for nuclear energy as the only United States uranium company with multiple central processing plants in operation. enCore operates the 100% owned and operated Rosita CPP in South Texas and the 70/30 joint venture Alta Mesa CPP with Boss Energy Ltd., with enCore operating as the project manager. The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore solely utilizes ISR for uranium extraction, a well-known and proven technology co-developed by the leaders at enCore Energy. Following upon enCore's demonstrated success in South Texas , future projects in enCore's planned project pipeline include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming . The Company holds other assets including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impact from corporate developments. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cision Canada
9 hours ago
- Cision Canada
enCore Energy Announces Filing of Early Warning Report
DALLAS, June 20, 2025 /CNW/ - enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the"Company" or "enCore"), America's Clean Energy Company ™, announces that it has disposed of 170,000,000 common shares in the capital of Anfield Energy Inc. (" Anfield") (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) in a private agreement at a price of $0.115 per share for aggregate proceeds of $19,550,000 (Canadian dollars). Immediately following the disposition, enCore holds or controls no common shares of Anfield. The disposition represents a 14.73% decrease in enCore's ownership or control over the outstanding common shares of Anfield on an undiluted basis. enCore does not currently hold or control any securities of Anfield. Since enCore's last early warning report dated January 15, 2024, enCore's holdings have decreased by an approximate 16.02% of the outstanding common shares of Anfield on an undiluted basis. enCore disposed of the shares of Anfield in a private transaction. enCore may, depending on market and other conditions, increase beneficial ownership of the Company's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities. The disclosure respecting enCore's shareholdings contained in this news release is made pursuant to National Instrument 62-103 and a report respecting the above disposition will be filed with the applicable securities commissions and will be available for viewing at A copy of the report may also be obtained by contacting Robert Willette, Acting Chief Executive Officer, or at [email protected]. About enCore Energy Corp. enCore Energy Corp., America's Clean Energy Company ™, is committed to providing clean, reliable, and affordable fuel for nuclear energy as the only United States uranium company with multiple central processing plants in operation. enCore operates the 100% owned and operated Rosita CPP in South Texas and the 70/30 joint venture Alta Mesa CPP with Boss Energy Ltd., with enCore operating as the project manager. The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore solely utilizes ISR for uranium extraction, a well-known and proven technology co-developed by the leaders at enCore Energy. Following upon enCore's demonstrated success in South Texas, future projects in enCore's planned project pipeline include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming. The Company holds other assets including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impact from corporate developments.
